key: cord-1002453-vhuctahq
authors: Dabbah, M. A.; Reed, A. B.; Booth, A. T. C.; Yassaee, A.; Despotovic, A.; Klasner, B.; Binning, E.; Aral, M.; Plans, D.; Labrique, A. B.; Mohan, D.
title: Machine learning approach to dynamic risk modeling of mortality in COVID-19: a UK Biobank cohort study
date: 2021-02-10
journal: nan
DOI: 10.1101/2021.02.08.21251343
sha: 1281c900e7f5fa90c3dfd02d28cdb545fea661f1
doc_id: 1002453
cord_uid: vhuctahq

The COVID19 pandemic has resulted in over two million deaths globally. There is an urgent need for robust, scalable monitoring tools supporting resource allocation and stratification of high-risk patients. This research aims to develop and validate prediction models, using the UK Biobank to estimate COVID19 mortality risk in confirmed cases. We developed a random forest classification model using baseline characteristics, pre-existing conditions, symptoms, and vital signs, such that the score could dynamically assess risk of mortality with disease deterioration (AUC: 0.92). The design and feature selection of the framework lends itself to deployment in remote settings. Possible applications include supporting individual-level risk profiling and monitoring disease progression across high volumes of patients with COVID19, especially in hospital-at-home settings. The COVID19 pandemic has precipitated over 100 million confirmed cases and 2.3 million deaths globally. The impact of the pandemic has not been limited to healthcare systems: a ripple effect has resulted in wide-ranging economic and social disruption. Interventions to reduce transmission, such as lockdowns, travel restrictions, and re-allocation of health resources, are critical to limiting the impact. Although large-scale vaccination programmes have begun, many countries globally will not have widespread access to vaccines until 2023, meaning that non-pharmaceutical interventions are likely to remain indispensable national strategies for some time. COVID19 shows highly varied clinical presentation. A significant proportion (17 to 45%) of cases are asymptomatic and require no specific care. Conversely, reviews of severe complications have found that up to 32% of hospitalized COVID19 patients are admitted to ICU7. Between these two extremes, typical symptoms include fever, continuous cough, anosmia, and dyspnoea, which may range from requiring only self-management at home to inpatient care. Understanding which individuals are most vulnerable to severe disease, and thereby in most need of resources, is critical to limit the impact of the virus. Decision-making at all levels requires an understanding of individuals risk of severe disease. Various patient characteristics, comorbidities, and lifestyle factors have been linked to greater risk of death and/or severe illness following infection. Furthermore, socioeconomic factors have also been linked as risk factors for COVID19 mortality. Once patients are infected with SARS CoV 2, additional physiological parameters, such as symptoms and vital signs, can inform real-time prognostication13. Laboratory testing and imaging can also inform risk stratification for early, aggressive intervention, though this data is only accessible to hospital inpatients, who are likely to be already severely affected. Robust, predictive models for acquisition and prognosis of COVID 1916 18 and resource management have been developed to support risk stratification and population management at scale, offering important insights for organizational decision-making. However, the individual is currently overlooked, and granular, patient-specific risk-scoring could potentially unify decision-making at all levels. Existing individualized risk scores, however, often conflate risk of COVID19 acquisition with risk of mortality following infection, which can limit their utility in patient management. For prediction models to achieve impact at scale, assessment of risk factors should be inexpensive and accessible to the general population, ideally without the need for specialized testing or hospital visits. Such risk prediction tools, enabling improved patient triage, could be used to further increase the efficiency of, and confidence in, hospital at home solutions, which have shown promise in reducing hospital burden throughout the pandemic. Risk scores in these circumstances need to be dynamic and contemporaneous, ideally incorporating symptoms and vital sign data to maximise utility to clinical and research teams. Therefore, the primary aim of this study is to develop and validate a population-based prediction model, using a large, rich dataset and a selective, clinically informed approach, which dynamically estimates the COVID19 mortality risk in confirmed diagnoses.

The COVID-19 pandemic has precipitated over 100 million confirmed cases and 2.3 million deaths globally 1 .

The impact of the pandemic has not been limited to healthcare systems: a ripple effect has resulted in wideranging economic and social disruption 2 . Interventions to reduce transmission, such as lockdowns, travel restrictions, and re-allocation of health resources, are critical to limiting the impact 3 . Although large-scale vaccination programmes have begun, many countries globally will not have widespread access to vaccines until 2023, meaning that non-pharmaceutical interventions are likely to remain indispensable national strategies for some time 4 .

COVID-19 shows highly varied clinical presentation. A significant proportion (17-45%) of cases are asymptomatic and require no specific care 5, 6 . Conversely, reviews of severe complications have found that up to 32% of hospitalized COVID-19 patients are admitted to ICU 7 . Between these two extremes, typical symptoms include fever, continuous cough, anosmia, and dyspnoea, which may range from requiring only selfmanagement at home to inpatient care. Understanding which individuals are most vulnerable to severe disease, and thereby in most need of resources, is critical to limit the impact of the virus.

Decision-making at all levels requires an understanding of individuals' risk of severe disease. Various patient characteristics, comorbidities, and lifestyle factors have been linked to greater risk of death and/or severe illness following infection [8] [9] [10] . Furthermore, socioeconomic factors have also been linked as risk factors for COVID-19 mortality 11, 12 . Once patients are infected with SARS-CoV-2, additional physiological parameters, such as symptoms and vital signs, can inform real-time prognostication 13 . Laboratory testing and imaging can also inform risk stratification for early, aggressive intervention, though this data is only accessible to hospital inpatients, who are likely to be already severely affected 14, 15 .

Robust, predictive models for acquisition and prognosis of COVID-19 [16] [17] [18] and resource management 19, 20 have been developed to support risk stratification and population management at-scale, offering important insights for organizational decision-making. However, the individual is currently overlooked, and granular, patient-specific risk-scoring could potentially unify decision-making at all levels. Existing individualized risk scores, however, often conflate risk of COVID-19 acquisition with risk of mortality following infection 16, 17 , which can limit their utility in patient management.

For prediction models to achieve impact at scale, assessment of risk factors should be inexpensive and accessible to the general population, ideally without the need for specialized testing or hospital visits. Such risk prediction tools, enabling improved patient triage, could be used to further increase the efficiency of, and confidence in, hospital-at-home solutions, which have shown promise in reducing hospital burden throughout the pandemic 21 . Risk scores in these circumstances need to be dynamic and contemporaneous, ideally incorporating symptoms and vital sign data to maximise utility to clinical and research teams. Therefore, the primary aim of this study is to develop and validate a population-based prediction model, using a large, rich dataset and a selective, clinically informed approach, which dynamically estimates the COVID-19 mortality risk in confirmed diagnoses.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251343 doi: medRxiv preprint

Summary population There were 7,536 adults (aged 51-85 yrs, mean: 67.4, SD: 8.8) from the UK Biobank (UKB) included in the analysis, of whom 496 (6.6%) had died as a result of COVID-19. The mean age of survivors was 66.8 years (SD: 8.7), compared to 75.9 years (SD: 8.7) for those that died. The most common pre-existing conditions in patients were hypertension (37.6%), osteoarthritis (24.3%), and chronic ischemic heart disease (13.2%) ( Table   1) . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. Table 1 . Descriptive characteristics of the UK Biobank cohort with positive COVID-19 test results. Preexisting medical conditions included only when reported more than one week prior to COVID-19 positive test result. Symptoms and vitals included only from primary care (GP) records when reported within +/-two weeks of COVID-19 positive test result. MND = motor neurone disease; MS = multiple sclerosis; HD = Huntington's disease. * Oxygen saturation, respiratory rate, and body temperature were included in the initial analysis, however, they were removed from the model due to low data availability.

The evaluation of the model is organised into two parts: the machine learning data-driven approach; and the machine learning and clinically selective approach. From an optimisation perspective, the objective of the model is to reduce the full feature array to a minimal subgroup (Figure 1 ) while maintaining a high prediction accuracy for COVID-19 mortality.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251343 doi: medRxiv preprint Figure 1 . Workflow for model development and feature selection. A) Conceptual diagram of the data ingestion pipeline and analysis methods. To combine databases, several data pre-processing steps were carried out, including: sanitisation (eliminating redacted records and nuanced entries); normalization (scaling values to ensure fitting with a reasonable range for further processing); time filtering; duration calculation (computing the time interval between testing positive and mortality); missing value substitution (replacing missing values or records with the mean value of the UK Biobank database); augmentation (bringing all data for each subject into a single unified record); and one-hot-encoding (codifying the presence of a pre-existing condition or symptom into a binary sequence for each subject). This data ingestion process standardized the input features and attributes for all subjects in this study regardless of their unique and variable conditions, symptoms, vital signs, and records. B) Illustration of the data-driven and clinically reviewed feature refinement process. AUC = area under the curve; GP = general practice; LOO = Leave-One-Out; ROC = receiver operating characteristic.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251343 doi: medRxiv preprint As shown, the ROC curves for the RF and CPH are very comparable with a slight advantage for the CPH. From Figure 2A , it can be seen that when QCOVID is applied to the UKB dataset it performs well and achieves an AUC of 0.83, showcasing robustness to unseen data. To explore the performance further, it is essential to look at the robustness of the generated models. Figure 2B illustrates the use of F-β statistical analysis to examine the performance of the various models. As expected, despite the CPH having a slightly greater AUC score, it is clear that the RF has much more stable performance. Moreover, it can be seen that both the CPH and QCOVID models achieve optimal F-β scores when β is small. However, for the RF model, the F-β scores are considerably larger than its comparators and are more consistent across the range of thresholds, thereby demonstrating greater stability and increased capabilities regarding recall (i.e. minimizing false-negatives).

This study developed and validated machine learning models to predict mortality in patients with COVID-19

using comprehensive data from 7,536 COVID-19 patients in the UKB. The results show that using easily . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251343 doi: medRxiv preprint accessible patient characteristics, brief medical history, symptoms, and vital signs can predict mortality in patients with COVID-19 with excellent levels of accuracy (AUC: 0.92).

The features selected in the presented model mirror much of the current clinical understanding regarding factors associated with severe COVID-19 outcomes. While research on COVID-19 is rapidly evolving, it is well established that age 23 and obesity 24 are significant variables. In the data-driven model, we found that age was the most critical factor in determining outcome, in line with meta-analyses on outcomes in COVID-19 patients 10, 23 .

Obesity is also well reflected in our model, with body mass index (BMI) and related measures featuring dominantly in the data-driven ranking. Potentially mediated by proinflammatory states induced by adiposity, the pathophysiological link between adiposity and severe COVID-19 outcomes is not fully understood, body composition may provide more granular risk profiling than BMI alone 25, 26 . The highest ranking pre-existing conditions were found to be type 2 diabetes and hypertension. While both conditions are linked to obesity, diabetes has been reported to confer significant independent mortality risk 27 . Evidence for the role of hypertension as an independent risk factor, however, is not fully established, with meta-analyses finding hypertension non-significant after adjusting for other risk factors 10, 28, 29 .

Alongside the specific COVID-19 data releases, the unique value of the UKB can be attributed to its wellestablished, longitudinal background dataset. Encompassing non-traditional health data, including anthropometric measurements and lifestyle insights, allows for the assessment of commonly overlooked, yet easily collectable, variables to enrich the already-documented clinical factors. The ability to capture a deeper phenotype of the individual prior to infection has proved integral to our model's performance, in line with the findings of other disease-specific prediction models developed on the UKB [30] [31] [32] . Notably, we identified baseline hip circumference, waist circumference, weight, and height to be valuable independent of BMI and obesity, accounting for four of the top-ten RF ranked features (Supplementary Figure 3) . Moreover, while baseline sleep duration has been demonstrated to be highly predictive of all-cause mortality 33 , cardiovascular diseases 34 , and type 2 diabetes 35 , this marks the first instance of its significant predictive influence within COVID-19 prognosis.

As a result of the data-driven approach, our most interesting findings concern the impact of prior urinary tract infection (UTI), respiratory failure, acute kidney failure, bacterial and non-bacterial pneumonias, and other bacterial infections. In the case of all but UTI, dividing each feature into time groupings by their proximity to the COVID-19 diagnosis highlights attenuated risk the more distant the event, returning to approximately baseline when >12 months for both the respiratory conditions and other infections. Interestingly, the outlying significance of acute kidney failure at >12 months suggests the impact of damage to this organ may be more integral to COVID-19 prognosis than that of the respiratory system. This is supported by findings related to UTIs, where they appear as a less damaging, but persistent, risk factor regardless of the time since diagnosis.

Respiratory and kidney complications are a hallmark of severe and fatal COVID-19, thus the observation that a history of severe conditions affecting these organs effectively forecasts COVID-19 prognosis is logical 36 . To date, however, the relationship between less severe urogenital factors and COVID-19 has not been effectively assessed. A recent systematic review on urological manifestations found urinary symptoms were absent from all included studies 37 . Where data has been collected, sample sizes have been too low to draw strong conclusions.

Though the occurrence of de novo urinary symptoms has been documented without noticeable impact on . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251343 doi: medRxiv preprint prognosis 38, 39 , it has been previously suggested, and more recently evidenced, that the presence of pre-existing urinary conditions may be associated with a poorer disease prognosis proportional to their severity 40, 41 . Our investigation provides the first reliable evidence that a history of UTI is predictive of greater COVID-19 mortality risk. We hypothesise that the underlying nature of this association reflects poorer baseline health status which may not previously have been of clinical significance in the absence of a highly infective, fatal pathogen such as SARS-CoV-2. The COVID-19 pandemic has resulted in extraordinary acceptance of digital technology in healthcare 45 . As clinician:patient ratios are increasingly stretched 46 , risk assessment tools can support the streamlining of clinical time and resource prioritization, whether on a national, organizational, or patient level. Models such as those presented, can support the latter by monitoring patients at-scale and identifying those at-risk of severe illness, in real-time, and without requiring specialist equipment or clinical input. Notably, our focus on variables which are not presently assessed by clinicians to stratify patients in remote monitoring settings means such a model enriches the standard-of-care, rather than attempting to replace it through the amalgamation of currently utilised data.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021.

Algorithm performance may be further improved by inclusion of passive, continuous variables via smartphones or wearables. Establishing our model in a prospective healthcare setting may enable this when coupled with high quality, continuous vital sign information and replete data on the course of symptomatology. Similar digital phenotyping has also shown potential in predicting COVID-19 infection at early symptoms onset 47, 48 . We believe a combination of these two types of digital tools, in union with dedicated hospital-at-home services, may become considered standard practice in infectious disease management, particularly during historically resource-intense periods, such as annual influenza outbreaks.

While the use of the UKB is a key strength in the development of the model, there are associated limitations which may impact the generalizability of the model. The UKB cohort trends towards being healthier and wealthier than the general population, which poses a notable limitation when modeling noncommunicable diseases 49 . As COVID-19 acquisition, however, is determined by exposure, this limitation is minimised in our investigation. Separately, the UKB COVID-19 data subset is less likely to capture asymptomatic or non-severe cases, in part as such individuals may not have received a test or sought medical treatment, but predominantly owing to UKB's enrichment for older age resulting in lesser rates of such presentation. The restricted age distribution (51-85 years) may further limit generalization of our findings to outside of this age range, however, ONS figures show those aged 50+ have accounted for 98.06% of all COVID-19-related deaths in England and Wales 50 .

Although age is clearly an important feature, our sensitivity analysis (Supplementary Figure 2 ) demonstrated negligible performance drop, likely because much of the risk associated with older age is captured within other included features. One reason for using uniform leave-one-out (LOO) training is to overcome such issues of feature reliance and generalize the model as much as possible. The F-score in Figure 2B illustrates this robustness, however, this must be tested on a separate representative dataset for a conclusive answer. Several included risk factors (lifestyle and anthropometric data) were assessed over 10-years prior to the time of COVID-19 infection and may have since changed. Deterioration in these factors may be expected over time and, therefore, the findings may be biased towards the null. Despite these limitations, our robust development approach, paired with deep individual phenotyping, strengthens the evidence towards effective COVID-19 risk profiling. In addition to the limitations of the dataset, it is likely that there are regional variances in COVID-19

outcomes. As such, the model would strongly benefit from external validation, especially with the continued emergence of disruptive SARS-CoV-2 variants 51 .

While the model presented outperforms QCOVID (AUC: 0.92 vs. 0.83), and best efforts were made in the comparison, it cannot be considered a direct comparison. In replication of the QCOVID algorithms, variables were mapped to related fields in the UKB, however, we were unable to confirm these were fully paired.

Moreover, as the UKB is not linked to GP databases in the same manner, there were some missing variables (Supplementary Table 2 ). Importantly, contrasting with our purpose of supporting patient management, QCOVID is designed for population risk stratification to aid public health decision-making, and was used to exemplify the necessity of specific model design for specific purposes.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

For this study, only participants with a positive RT-PCR COVID-19 test, from English assessment centres who were alive on 19 th December 2020 were included (Supplementary Figure 1) . Public Health England provided data on SARS-CoV-2 tests, including the specimen date, location, and result 53 

Considering the chronology of medical events is critical to distinguish between, for example, pre-existing conditions and complications resulting from COVID-19. Specific attributes, therefore, can be included or excluded in the prediction model for various use cases. This study focuses on developing a model to predict mortality for COVID-19 patients before hospital admission. Accordingly, inclusion of respiratory failure (ICD-10: J96.9), for example, as a symptom or complication to predict mortality has limited use, as such events would . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251343 doi: medRxiv preprint demand hospital admission. Conversely, it is valuable to include personal history of respiratory failure as a prognostic indicator. Thus, we implemented a time filter for all features which were not demographics, symptoms, or vital signs, excluding any data recorded later than one-week prior to patients' positive COVID-19

test. This accounted for the circumstance whereby a patient may have been admitted for severe symptoms of COVID-19 prior to receiving a test. Further time filtering of <1 month, 1-12 months, and >12 months was applied to specific acute features to provide more granular insight. Similarly, it is important to consider only relevant symptoms and vital signs corresponding to the period of COVID-19 infection. Thus, a two-week window pre-and post-the first COVID-19 positive test was implemented.

The data ingestion pipeline, Figure 1A , generates an array of ~12,000 dimensions (including patient characteristics, pre-existing conditions, symptoms, and vital signs). Owing to the small number of samples in the dataset and the importance of obtaining an unbiased model, a LOO cross-validation experiment, which is closely related to the jack-knife estimation method 54 , was used to search the full feature array for the most relevant features. LOO iterates through every sample in the dataset, whereby at each step the current sample was used to evaluate the model trained on the remaining dataset. At each iteration the samples of all classes were balanced to ensure unbiased training and, following evaluation, the model was discarded and a new model trained. A RF model was chosen due to its inherent ability to extract features, handle high dimensionality data, and generalize well to unseen data 55 . During each step of the LOO cross-validation, a ranked list of features was extracted and averaged across the entire experiment to obtain a final shortlist of features that produced the highest accuracy, further cross-checked by clinical expertise. Figure 1B illustrates the production of shortlisted features driven by data, and their validation and review based on clinical judgement.

Clinical feature selection was informed by a review of ranked feature importance in RF model. The highest ranked 1,000 features were screened by at least two reviewers. Any disagreements were settled by consensus with input of additional reviewers. Features were excluded where: i) they could not be readily obtained through self-reporting or measured outside of the clinical setting; ii) there was high confounding with higher ranked features; iii) clinical consensus concluded that the feature's rank was more likely to be explained by database bias. Subsequently, features which were closely related (e.g. cancer diagnoses) were grouped together.

Supplementary ICD-10 codes were included and, where possible, generalized (Supplementary Table 1 ).

The LOO evaluation was selected to maximize the value of the available datasets. By evaluating one sample at each iteration, the rest of the samples could be used for training the model. By iterating on the entire dataset, each sample took turns to be the evaluation sample. At each iteration, the previously trained model was completely discarded and a new one trained. Another advantage of using the LOO was to ensure fair machine learning training by having enough samples to represent the different prediction classes uniformly.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251343 doi: medRxiv preprint

In this study, the prediction classes were two: COVID-19 survivors (n=7,040) and non-survivors (n=496). At each LOO iteration, two groups of equal sample size were randomly selected without replacement for training.

The evaluation sample outcome and RF likelihood value were aggregated from all iterations. After aggregating all the evaluation results from the LOO experiment, the ROC curve analysis was carried out, and the AUC computed as a measure of accuracy 55 . Furthermore, the F-β statistic was used to evaluate the robustness of the model. When β is 1, this becomes the F1-score, which gives equal weights to recall and precision. A smaller β value gives more weight to precision, minimising false-positive errors, while a larger β value gives more weight to recall, minimising false-negative errors. The F-score range is [0, 1], where a score of 1 is a perfect performance.

The machine learning algorithm used in this study is the RF, which is an ensemble meta-estimator constructed from several decision trees 55 . These trees were fitted to the data using the bootstrap aggregation method (or bagging), which is robust and resilient to over-fitting 56 

We compared our model against QCOVID, a leading risk prediction model for infection and subsequent death due to COVID-19, which was developed by fitting a sub-distribution hazard model on the QResearch database 16 . Predictor variables reported in QCOVID were mapped to comparable features in the UKB dataset.

The UKB dataset did not include all of the relevant variables used in the QCOVID algorithm, hence chemotherapy grades and medication variables were excluded in our analysis (Supplementary Table 2 ).

QCOVID risk equations for mortality were then implemented for both male and female cohorts. To ensure a fair comparison between models, QCOVID risk equations were evaluated on the UKB dataset using the same methods described above.

This article was written following the TRIPOD (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis) guidelines 57 , which are further elaborated in Supplementary Table 5 .

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard

The socio-economic implications of the coronavirus pandemic (COVID-19): A review

The impact of COVID-19 and strategies for mitigation and suppression in low-and middle-income countries

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

India's COVID-19 vaccinations to stretch to late 2022: study | The Journal Pioneer

Prevalence of Asymptomatic SARS-CoV-2 Infection

Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis

Rate of Intensive Care Unit admission and outcomes among patients with coronavirus: A systematic review and Meta-analysis

Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort

The Association Between Symptom Onset and Length of Hospital Stay in 2019 Novel Coronavirus Pneumonia Cases Without Epidemiological Trace

Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis

Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study

Disparities in the risk and outcomes of COVID-19

Vital signs assessed in initial clinical encounters predict COVID-19 mortality in an NYC hospital system

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Association of Red Blood Cell Distribution Width With Mortality Risk in Hospitalized Adults With SARS-CoV-2 Infection

Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study

Individual and community-level risk for COVID-19 mortality in the United States

Developing a COVID-19 mortality risk prediction model when individual-level data are not available

Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score

CPAS: the UK's national machine learning-based hospital capacity planning system for COVID-19

Mobile App-Based Remote Patient Monitoring in Acute Medical Conditions: Prospective Feasibility Study Exploring Digital Health Solutions on Clinical Workload During the COVID Crisis

Regression Models and Life-Tables

The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects

Global pandemics interconnected -obesity, impaired metabolic health and COVID-19

The role of visceral adiposity in the severity of COVID-19: Highlights from a unicenter cross-sectional pilot study in Germany

Obesity and SARS-CoV-2: A population to safeguard

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Patients with diabetes are at higher risk for severe illness from COVID-19

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Factors associated with COVID-19-related death using OpenSAFELY

Cardiovascular disease risk prediction using automated machine learning: A prospective study of 423,604 UK Biobank participants

Development and validation of risk prediction models for multiple cardiovascular diseases and Type 2 diabetes

Anthropometry, body fat composition and reproductive factors and risk of oesophageal and gastric cancer by subtype and subsite in the UK Biobank cohort

Sleep Duration and All-Cause Mortality: A Systematic Review and Meta-Analysis of Prospective Studies

Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies

Sleep Duration as a Risk Factor for Diabetes Incidence in a Large US Sample

A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions

De Novo Urinary Symptoms Associated With COVID-19: COVID-19-Associated Cystitis

Urinary Frequency as a Possibly Overlooked Symptom in COVID-19 Patients: Does SARS-CoV-2 Cause Viral Cystitis?

Focus on the Crosstalk between COVID-19 and Urogenital Systems

The Effect of the Presence of Lower Urinary System Symptoms on the Prognosis of COVID-19: Preliminary Results of a Prospective Study

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Clinical symptoms, comorbidities and complications in severe and non-severe patients with COVID-19

Prediction models for covid-19 outcomes

Applications of digital technology in COVID-19 pandemic planning and response

Chronic hospital nurse understaffing meets COVID-19: an observational study

Pre-symptomatic detection of COVID-19 from smartwatch data

Analyzing changes in respiratory rate to predict the risk of COVID-19 infection

Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population

Office for National Statistics. Deaths registered weekly in England and Wales

SARS-CoV-2 evolution and vaccines: cause for concern?

UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age

Dynamic linkage of COVID-19 test results between Public Health England's Second Generation Surveillance System and UK

The jackknife, the bootstrap, and other resampling plans

Random Forests

Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement